<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>404</id>
    <completedYear/>
    <publishedYear>2005</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst>104</pageFirst>
    <pageLast>106</pageLast>
    <pageNumber/>
    <edition/>
    <issue>2</issue>
    <volume>273</volume>
    <type>article</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">CD44-v6 concentrations in carcinoma of the uterine cervix: lack of prognostic significance</title>
    <abstract language="deu">Several kinds of cellular adhesion molecules, like different splicing variants of CD 44, have gained important as prognostic or markers for metastatic disease. Fresh frozen samples from 64 cervical carcinoma (CX) were stored in liquid nitrogen and examined using ELISA-technique, testing the prognostic impact. Normal cervical tissue served as control. CD 44-v6 concentration, was significant elevated in tumor tissue, when compared to the controls (P=0.04). There was no correlation to tumor stage (P=0.61), lymphovascular space involvement (P=0.075) or pelvic lymph node involvement (P=0.81). The CD 44-v6 concentration was not informative regarding recurrence-free and overall survival. Contrary to immunohistochemistry, the quantification of CD 44-v6 using ELISA-technique does not provide any further information.</abstract>
    <parentTitle language="eng">Archives of Gynecology and Obstetrics</parentTitle>
    <identifier type="doi">10.1007/s00404-005-0039-5</identifier>
    <enrichment key="BegutachtungStatus">peer-reviewed</enrichment>
    <author>Lars-Christian Horn</author>
    <author>Georgios Raptis</author>
    <author>Uta Fischer</author>
    <author>Bettina Hentschel</author>
    <author>U. Köhler</author>
    <author>Christine E. Richter</author>
    <author>Rosemarie Martin</author>
    <subject>
      <language>deu</language>
      <type>swd</type>
      <value>Gebärmutterhalskrebs</value>
    </subject>
    <subject>
      <language>deu</language>
      <type>swd</type>
      <value>Antigen CD44</value>
    </subject>
    <collection role="ddc" number="618">Gynäkologie, Geburtsmedizin, Pädiatrie, Geriatrie</collection>
    <collection role="institutes" number="FakIM">Fakultät Informatik und Mathematik</collection>
    <collection role="othpublikationsherkunft" number="">Externe Publikationen</collection>
    <collection role="persons" number="raptisehealth">Raptis, Georgios (Prof. Dr.) - eHealth Lab</collection>
    <collection role="othforschungsschwerpunkt" number="16314">Lebenswissenschaften und Ethik</collection>
    <collection role="institutes" number="">Labor eHealth (eH)</collection>
  </doc>
  <doc>
    <id>405</id>
    <completedYear/>
    <publishedYear>2006</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst>906</pageFirst>
    <pageLast>911</pageLast>
    <pageNumber/>
    <edition/>
    <issue>3</issue>
    <volume>103</volume>
    <type>article</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Pattern of invasion is of prognostic value in surgically treated cervical cancer patients</title>
    <abstract language="eng">Objectives: Different patterns of invasion (representing different grades of tumor cell dissociation) are associated with prognostic outcome in cancer. We evaluated the prognostic value of different patterns of invasion (PI) in cervical carcinomas (CX).&#13;
&#13;
Methods: Six hundred eleven surgically treated CX (FIGO IB to IIB) were re-evaluated histologically regarding the PI, using a three-level scoring system. Closed PI was defined as cohesive growth with well-delineated (pushing) borders. In finger-like PI the tumor grows in solid cords/trabecles. Highly dissociative growth in small groups or single cells was defined as spray-like PI. Types of PI were correlated to tumor stage, histo-morphologic factors and prognostic outcome.&#13;
&#13;
Results: Sixty percent of the tumors showed a spray-like PI, 30% a finger-like PI and only 7.4% were of the closed type. Spray-like PI showed a significant correlation with advanced stage disease, lymphovascular space involvement, poorly differentiated tumors and pelvic lymph node metastases. Spray-like PI was accompanied by a reduced 5-year overall survival when compared to the finger-like and closed PI (68.7% vs. 80.9% vs. 88.5%; P=0.0004). The prognostic impact of the PI disappeared in node-positive patients (P=0.06) but persisted in patients without pelvic lymph node disease (P=0.03). In multivariate analysis, using COX regression model, the PI represented as independent prognostic factor.&#13;
&#13;
Conclusions: Spray-like PI (i.e., highest degree of tumor cell dissociation) is associated with advanced tumor stages, increased rate of recurrency and a reduced overall survival. In separate analysis of patients with and without lymph node metastases, the impact of PI persisted only in node-negative cases as a prognostic factor.</abstract>
    <parentTitle language="eng">Gynecologic Oncology</parentTitle>
    <identifier type="doi">10.1016/j.ygyno.2006.05.046</identifier>
    <author>Lars-Christian Horn</author>
    <author>Uta Fischer</author>
    <author>Georgios Raptis</author>
    <author>Karin Bilek</author>
    <author>Bettina Hentschel</author>
    <author>Christine E. Richter</author>
    <author>Ulf Dietrich Braumann</author>
    <author>Jens Einenkel</author>
    <subject>
      <language>deu</language>
      <type>swd</type>
      <value>Gebärmutterhalskrebs</value>
    </subject>
    <subject>
      <language>deu</language>
      <type>swd</type>
      <value>Chirurgie</value>
    </subject>
    <subject>
      <language>deu</language>
      <type>swd</type>
      <value>Metastase</value>
    </subject>
    <collection role="ddc" number="618">Gynäkologie, Geburtsmedizin, Pädiatrie, Geriatrie</collection>
    <collection role="institutes" number="FakIM">Fakultät Informatik und Mathematik</collection>
    <collection role="othpublikationsherkunft" number="">Externe Publikationen</collection>
    <collection role="persons" number="raptisehealth">Raptis, Georgios (Prof. Dr.) - eHealth Lab</collection>
    <collection role="othforschungsschwerpunkt" number="16314">Lebenswissenschaften und Ethik</collection>
    <collection role="institutes" number="">Labor eHealth (eH)</collection>
  </doc>
  <doc>
    <id>406</id>
    <completedYear/>
    <publishedYear>2007</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst>310</pageFirst>
    <pageLast>315</pageLast>
    <pageNumber/>
    <edition/>
    <issue>2</issue>
    <volume>107</volume>
    <type>article</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Tumor size is of prognostic value in surgically treated FIGO stage II cervical cancer</title>
    <abstract language="deu">Objectives&#13;
Tumor size is a well recognized prognostic factor in early stage cervical carcinoma (CX). However, limited knowledge exists about the value of tumor size in surgically treated CX with extrauterine extension.&#13;
&#13;
Methods&#13;
245 cases of local advanced CX (FIGO stage IIA and IIB) who received upfront surgery were evaluated regarding tumor size, regarding the prediction of pelvic lymph node involvement and recurrence free and overall survival during a median follow-up time of 54 months (95% CI 45.4–62.6 months). Tumors larger than 4 cm were defined as bulky stage disease.&#13;
&#13;
Results&#13;
Bulky disease was seen in 46.1% (113/245). 60.2% of these patients showed pelvic lymph node involvement, compared to 42.4% (56/132) in non-bulky tumors (p = 0.006; odds ratio: 2.2 [95% CI: 1.3–3.6]). Patients with bulky tumors showed an increase of recurrent disease (40.2% vs. 28.0%; p = 0.045). The relative risk for recurrent disease was 1.97 (95% CI: 1.3–3.0). The 5-year overall survival rate was significantly lower (67.7% [95% CI: 58.2–74.8] vs. 49.5% [95% CI: 36.8–59.1]; p = 0.0015). In multivariate analysis, tumor stage, pelvic lymph node involvement and maximal tumor size were independent prognostic factors.&#13;
&#13;
Conclusions&#13;
The results suggest that tumor size, defining bulky disease as tumors larger than 4 cm, is of prognostic impact also in FIGO stage II cervical carcinomas. A revised FIGO/TNM classification system similar to the subgrouping of stage IB CX is recommended for stage II using a cut-off value of 4 cm as discriminator: stage IIA1 and stage IIB1 for tumors with ≤ 4 cm and IIA2 and IIB2 for tumors &gt; 4 cm (i.e. bulky disease).</abstract>
    <parentTitle language="eng">Gynecologic Oncology</parentTitle>
    <identifier type="doi">10.1016/j.ygyno.2007.06.026</identifier>
    <author>Lars-Christian Horn</author>
    <author>Uta Fischer</author>
    <author>Georgios Raptis</author>
    <author>Karin Bilek</author>
    <author>Bettina Hentschel</author>
    <subject>
      <language>deu</language>
      <type>swd</type>
      <value>Gebärmutterhalskrebs</value>
    </subject>
    <subject>
      <language>deu</language>
      <type>swd</type>
      <value>Chirurgie</value>
    </subject>
    <subject>
      <language>deu</language>
      <type>swd</type>
      <value>Tumorwachstum</value>
    </subject>
    <collection role="ddc" number="618">Gynäkologie, Geburtsmedizin, Pädiatrie, Geriatrie</collection>
    <collection role="institutes" number="FakIM">Fakultät Informatik und Mathematik</collection>
    <collection role="othpublikationsherkunft" number="">Externe Publikationen</collection>
    <collection role="persons" number="raptisehealth">Raptis, Georgios (Prof. Dr.) - eHealth Lab</collection>
    <collection role="othforschungsschwerpunkt" number="16314">Lebenswissenschaften und Ethik</collection>
    <collection role="institutes" number="">Labor eHealth (eH)</collection>
  </doc>
  <doc>
    <id>403</id>
    <completedYear/>
    <publishedYear>2004</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst>385</pageFirst>
    <pageLast>388</pageLast>
    <pageNumber/>
    <edition/>
    <issue>4</issue>
    <volume>42</volume>
    <type>article</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Clinical relevance of urokinase-type plasminogen activator and its inhibitor type-1 (PAI-1) in squamous cell carcinoma of the uterine cervix</title>
    <abstract language="eng">Objective&#13;
&#13;
The expression of uPA and PAI‐1 as parameters of tumour‐associated proteolysis has been implicated in the process of tumour cell invasion and the metastatic process. However, there is limited information on the impact of these parameters in cervical carcinoma.&#13;
Methods&#13;
&#13;
Quantitative levels for uPA (n = 114) and PAI‐1 (n = 103) were researched in operatively treated, surgically staged squamous cell cancer of the uterine cervix, using an ELISA‐technique. Results were assessed regarding their impact in predicting pelvic lymph nodes metastases, tumour recurrence rate and recurrence free survival (RFS) using uni‐ and multivariate analysis.&#13;
Results&#13;
&#13;
Median levels of both parameters were significantly higher in tumour tissue than in normal cervical tissue (p &lt; 0.001). Detection of uPA gave no useful prognostic information. PAI‐1 concentration showed a positive correlation with advanced tumour stage (p = 0.008), but no significant correlation with nodal status (pN0: 2.6 vs. pN1: 4.0 ng/mg protein; p = 0.092). Using a cut‐off level of 2.4 ng/mg protein, patients with elevated PAI‐1 levels demonstrated reduced RFS (45.9 versus 52.9 months; p = 0.1). Multivariate analysis, including nodal status, tumour stage, lymphovascular space involvement and grading failed to demonstrate any prognostic impact of uPA and PAI‐1.&#13;
Conclusions&#13;
&#13;
The results indicate, that PAI‐1 expression is of some prognostic impact in cervical cancer, indicating an association of elevated PAI levels with local tumour progression and reduced recurrence‐free survival.</abstract>
    <parentTitle language="eng">Australian and New Zealand Journal of Obstetrics and Gynaecology</parentTitle>
    <identifier type="doi">10.1111/j.0004-8666.2002.00385.x</identifier>
    <author>Lars-Christian Horn</author>
    <author>S. Pippig</author>
    <author>Georgios Raptis</author>
    <author>Uta Fischer</author>
    <author>U. Köhler</author>
    <author>Bettina Hentschel</author>
    <author>Rosemarie Martin</author>
    <subject>
      <language>deu</language>
      <type>swd</type>
      <value>Plasminogen human-Aktivator</value>
    </subject>
    <subject>
      <language>deu</language>
      <type>swd</type>
      <value>Urokinase</value>
    </subject>
    <subject>
      <language>deu</language>
      <type>swd</type>
      <value>squamöser Krebs</value>
    </subject>
    <subject>
      <language>deu</language>
      <type>swd</type>
      <value>Gebärmutterhals</value>
    </subject>
    <collection role="ddc" number="618">Gynäkologie, Geburtsmedizin, Pädiatrie, Geriatrie</collection>
    <collection role="institutes" number="FakIM">Fakultät Informatik und Mathematik</collection>
    <collection role="othpublikationsherkunft" number="">Externe Publikationen</collection>
    <collection role="persons" number="raptisehealth">Raptis, Georgios (Prof. Dr.) - eHealth Lab</collection>
    <collection role="othforschungsschwerpunkt" number="16314">Lebenswissenschaften und Ethik</collection>
    <collection role="institutes" number="">Labor eHealth (eH)</collection>
  </doc>
</export-example>
